Raoul Tibes

10.0k total citations · 1 hit paper
144 papers, 5.3k citations indexed

About

Raoul Tibes is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Raoul Tibes has authored 144 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Molecular Biology, 70 papers in Hematology and 33 papers in Genetics. Recurrent topics in Raoul Tibes's work include Acute Myeloid Leukemia Research (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers) and Chronic Myeloid Leukemia Treatments (20 papers). Raoul Tibes is often cited by papers focused on Acute Myeloid Leukemia Research (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers) and Chronic Myeloid Leukemia Treatments (20 papers). Raoul Tibes collaborates with scholars based in United States, Germany and Canada. Raoul Tibes's co-authors include Glen J. Weiss, Daniel D. Von Hoff, Mitesh J. Borad, Steven M. Kornblau, Michael Andreeff, Gordon B. Mills, Charles M. Rudin, Patricia LoRusso, Ruben A. Mesa and Josina C. Reddy and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Raoul Tibes

139 papers receiving 5.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raoul Tibes United States	34	3.6k	1.5k	1.4k	771	578	144	5.3k
Lia Gore United States	43	2.6k 0.7×	2.6k 1.7×	1.1k 0.8×	673 0.9×	763 1.3×	202	6.1k
Hetty E. Carraway United States	35	1.7k 0.5×	1.1k 0.7×	1.4k 1.0×	815 1.1×	265 0.5×	212	3.6k
José A. Martínez-Climent Spain	39	1.9k 0.5×	1.3k 0.9×	952 0.7×	865 1.1×	1.0k 1.8×	135	4.5k
Benjamin Esterni France	32	1.4k 0.4×	2.2k 1.5×	1.0k 0.7×	422 0.5×	489 0.8×	75	4.4k
Carla S. Wilson United States	21	2.3k 0.6×	1.7k 1.1×	2.8k 2.0×	736 1.0×	501 0.9×	37	4.3k
Pier Francesco Ferrucci Italy	37	2.9k 0.8×	3.7k 2.5×	1.2k 0.8×	337 0.4×	439 0.8×	141	6.2k
Margaret Dugan United States	29	1.9k 0.5×	2.5k 1.7×	1.4k 1.0×	2.2k 2.9×	658 1.1×	71	6.2k
Yasuhiro Oki United States	40	2.2k 0.6×	2.3k 1.6×	1.3k 0.9×	1.7k 2.2×	3.1k 5.4×	207	6.3k
Alexander Laird United States	32	2.7k 0.7×	1.7k 1.1×	664 0.5×	434 0.6×	603 1.0×	97	4.9k
J Garcı́a-Conde Spain	35	954 0.3×	2.0k 1.4×	984 0.7×	792 1.0×	1.1k 1.9×	104	3.9k

Countries citing papers authored by Raoul Tibes

Since Specialization

Citations

This map shows the geographic impact of Raoul Tibes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raoul Tibes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raoul Tibes more than expected).

Fields of papers citing papers by Raoul Tibes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raoul Tibes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raoul Tibes. The network helps show where Raoul Tibes may publish in the future.

Co-authorship network of co-authors of Raoul Tibes

This figure shows the co-authorship network connecting the top 25 collaborators of Raoul Tibes. A scholar is included among the top collaborators of Raoul Tibes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raoul Tibes. Raoul Tibes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tibes, Raoul, Heidi Kosiorek, Amylou C. Dueck, et al.. (2023). Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. Cancer. 129(15). 2321–2330. 7 indexed citations

Al‐Kali, Aref, Raoul Tibes, Pamela J. Atherton, et al.. (2023). A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. American Journal of Hematology. 98(3). 472–480. 5 indexed citations

Konopleva, Marina, Nitin Jain, Courtney L. Andersen, et al.. (2021). NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies. Blood. 138(Supplement 1). 2353–2353. 5 indexed citations

Kraus, Sabrina, Alexander Dierks, Leo Rasche, et al.. (2021). ⁶⁸Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. Journal of Nuclear Medicine. 63(1). 96–99. 20 indexed citations

Chen, Xufeng, Christina Glytsou, Hua Zhou, et al.. (2019). Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discovery. 9(7). 890–909. 214 indexed citations

Webster, Jonathan, Raoul Tibes, Amanda L. Blackford, et al.. (2017). Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research. 61. 108–116. 44 indexed citations

Tibes, Raoul. (2016). Sonidegib phosphate: new approval for basal cell carcinoma. Drugs of today. 52(5). 295–295. 1 indexed citations

Ravandi, Farhad, Ivana Gojo, Mrinal M. Patnaik, et al.. (2016). A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48. 92–100. 48 indexed citations

Braggio, Esteban, Scott Van Wier, Juhi Ojha, et al.. (2015). Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clinical Cancer Research. 21(17). 3986–3994. 150 indexed citations

10.

Ho, Thai H., Huihuang Yan, Jin G. Park, et al.. (2015). A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS ONE. 10(7). e0132831–e0132831. 7 indexed citations

11.

Weiss, Glen J., et al.. (2012). 18‐FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Medicine. 1(2). 230–236. 20 indexed citations

12.

Mahadevan, Daruka, Donald W. Northfelt, Pavani Chalasani, et al.. (2012). Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. International Journal of Clinical Oncology. 18(5). 934–941. 18 indexed citations

13.

Weiss, Glen J., Jeffrey R. Infante, E. Gabriela Chiorean, et al.. (2011). Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 17(9). 2997–3004. 122 indexed citations

14.

LoRusso, Patricia, Charles M. Rudin, Josina C. Reddy, et al.. (2011). Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(8). 2502–2511. 420 indexed citations

15.

Kundranda, Madappa N., Raoul Tibes, & Ruben A. Mesa. (2011). Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?. Current Hematologic Malignancy Reports. 7(1). 78–86. 21 indexed citations

16.

Tibes, Raoul, et al.. (2010). Hedgehog antagonist GDC‐0449 is effective in the treatment of advanced basal cell carcinoma. The Laryngoscope. 120(12). 2456–2459. 25 indexed citations

17.

Arora, Shilpi, Kristen Bisanz, Gargi D. Basu, et al.. (2010). RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecologic Oncology. 118(3). 220–227. 48 indexed citations

18.

Anthony, Stephen P., William L. Read, Peter J. Rosen, et al.. (2008). Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity. Journal of Clinical Oncology. 26(15_suppl). 2531–2531. 8 indexed citations

19.

Tibes, Raoul, Antonio Jimeno, Daniel D. Von Hoff, et al.. (2008). Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125. Journal of Clinical Oncology. 26(15_suppl). 3531–3531. 13 indexed citations

20.

Tibes, Raoul, Yiling Lu, Doris R. Siwak, et al.. (2005). Identification of selective inhibition of phospho-S6 ribosomal protein in XK469 sensitive leukemia cell lines using functional proteomic analysis. Cancer Research. 65. 772–772. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact